1[1]Bussolati O,Belletti S,Uggeri J,et al.Characterization of apoptotic phenomena induced by treatment with L-asparaginase in NIH-3T3 cells.Exp Cell Res,1995,220:283- 291.
2[2]Boos J,Werber G,Ahlke E,et al.Monitoring of asparaginase activity and asparagines levels in children of different asparaginase preparations.Eur J Cancer,1996,32A(9):1544- 1550.
3[3]Ahlke E,Nowak-G ttl U,Schulze-Westhoff P,et al.Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukemia.Br J Hematol,1997,96:675- 681.
4[4]Boos J.Pharmacokinetics and drug monitoring of L-asparaginase treatment.Int J Clin Pharm Ther,1997,35(3):96- 98.
5[5]Rizzari C,Zucchetti M,Conter V,et al.L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m.or i.v.Erwinia C.or E.coli L-asparagin- ase as first exposure.Ann Oncol,2000,11:189- 193.
6[6]Billett AL,Carls A,Gelber RD,et al.Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to E.coli asparaginase.Can- cer,1992,70:201- 206.
7[7]Whoo MH,Hak MC,Evans WE,et al.Anti-asparaginase antibodies following E.coli asparaginase therapy in pediatric acute lymphoblastic leukemia.Leukemia,1998,12:1527- 1533.
8[8]Wang B,Hak LJ,Relling MV,et al.ELISA to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemia.J Immunol Meth,2000,239:75- 83.
9[9]Wanger A,Boos J.Unphysiological effects contributing to asparaginase toxicity in vitro. Am J physiol,1998,274(4ptl):c1185- c1186.
10[10]Codegoni AM,Biondi A,Conter V,et al.Human monocytic leu- kemia expresses low levels of asparagines synthase and is potentially sensitive to L-asparaginase.Leukemia,1995,9(2):360- 361.
